Cemiplimab for Secondary Angiosarcomas

Sponsor
Radboud University Medical Center
Study ID
NCT04873375
Phase
PHASE2
Status
Completed

Conditions

  • Locally Advanced Sarcoma
  • Metastasis
  • Secondary Angiosarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cemiplimab — DRUG
    After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks

Study Details

Secondary angiosarcomas are aggressive mesenchymal tumors with a poor prognosis and limited therapeutic options. Recent studies conducted in patients with cutaneous squamous-cell carcinoma provide evidence that cemiplimab has the potential to be an effective treatment also for patients with secondary angiosarcomas. The purpose of this study is to evaluate the overall response rate after 24 weeks of cemiplimab treatment in patients with locally advanced or metastatic secondary angiosarcomas. The investigators hypothesis is that cemiplimab could be an effective treatment for patients diagnosed with locally advanced and metastatic secondary angiosarcomas.

Key Dates

Start date
Jan 1, 2022
Status verified
Jun 2024
Primary completion
Oct 9, 2024
Completion
Oct 18, 2024

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cemiplimab
    After inclusion, all patients will be treated with Cemiplimab 350mg intravenously every three weeks

Primary Outcome Measure

Overall Response Rate (ORR) after 24 weeks of cemiplimab [ Time Frame: From the date of study inclusion until 24 weeks after inclusion. Interim analysis after 13 patients ]

Related Studies